Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ferric iron reduction is the biochemical conversion of ferric iron (Fe³⁺) to ferrous iron (Fe²⁺) through electron transfer. This process is catalyzed by a diverse group of enzymes called ferric iron reductases, present in bacteria, yeasts, and higher organisms. In microbes, ferric iron serves as a terminal electron acceptor under anaerobic conditions (dissimilatory iron reduction), while in most eukaryotes—including humans—ferric reductases enable cellular iron uptake and homeostasis (assimilatory iron reduction). The underlying mechanisms involve the transfer of electrons from species like flavins or cytochromes to Fe³⁺, either at the cell surface or within organelles. Disruption of this process impacts iron bioavailability, with physiological relevance in anemia, infection, and metabolic disorders.
Reduction of ferric iron (Fe³⁺) to ferrous iron (Fe²⁺) using electrons donated from flavins, cytochromes, or NAD(P)H. Generation of proton motive force during microbial respiration (dissimilatory process).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ferric iron reduction.